2 Dividend Stocks to Buy and Hold For 10 Years

Core Insights - The article emphasizes the resilience of dividend stocks, particularly Bristol Myers Squibb and Amgen, as attractive long-term investments despite facing challenges like patent cliffs [2][8][14] Group 1: Bristol Myers Squibb - Bristol Myers Squibb's stock has underperformed over the past year due to patent cliffs but has a strong product lineup, especially in oncology [3][8] - The company is introducing new formulations, such as a subcutaneous version of Opdivo, to mitigate competition from generics [4] - Bristol Myers has promising candidates in its pipeline, including BMS-986446 for Alzheimer's disease, which has received Fast Track Designation from the FDA [6][7] - The company has a forward dividend yield of 4.4% and has increased its payouts by 65.8% over the past decade, making it an attractive income stock [8] Group 2: Amgen - Amgen is facing challenges from a recent patent cliff but has strong growth drivers, including Tezspire for asthma and Tepezza for thyroid eye disease [9][10] - The company has a robust pipeline, including investigational drugs like MariTide for diabetes and weight management, which are in phase 3 studies [12][13] - Amgen's dividend yield is over 3%, and it has consistently increased its dividend since 2011, indicating a secure dividend program for income-seeking investors [14]